Abstract B072: Resistance to the RAS inhibitor daraxonrasib due to the LZTR1 mutation in a KRAS G12D mutated pancreatic ductal adenocarcinoma patient-derived organoid model
Targeted therapy with RAS (Rat sarcoma) inhibitors are increasingly used in the treatment of pancreatic ductal adenocarcinoma (PDAC) given the prevalence of KRAS (Kirsten rat sarcoma virus) mutations in over 90% and poor prognosis with 13.7% five-year survival in this population despite standard treatment.1,2 Leu...